AKT1 and neoplasm: The findings indicate that abemaciclib, in combination with RT, enhanced tumor cell radiosensitivity, enhanced gamma-H2AX phosphorylation, reduced AKT phosphorylation, attenuated PI3K/mTOR signaling, alleviated radiation-induced vasculogenesis, and enhanced tumor growth delay (Naz et al. 2019).